Full-Time

Postdoctoral Scientist

Posted on 9/4/2025

Schrödinger

Schrödinger

1,001-5,000 employees

Computational platform for drug discovery

Compensation Overview

$90k/yr

Cambridge, MA, USA + 1 more

More locations: Framingham, MA, USA

In Person

Category
Biology & Biotech (4)
, , ,
Requirements
  • PhD in Chemistry, Biochemistry, Biophysics, or a related field
  • Proficiency in measuring the affinity of protein/ligand interactions
Responsibilities
  • Perform protein purification
  • Execute wet-lab biophysical ligand-binding experiments, such as SPR and ITC
  • Make computational modeling calculations, such as molecular dynamics and free energy perturbation simulations
Desired Qualifications
  • Experience with surface plasmon resonance and isothermal titration calorimetry to measure protein/ligand affinity
  • Ability to solve protein/ligand structures by X-ray crystallography
  • Familiarity with the Schrödinger platform
  • Proficient Python programming
  • Excellent verbal and written communication
  • Ability to conduct independent research

Schrödinger provides a computational platform for drug discovery used by biopharmaceutical companies, academic institutions, and government laboratories around the world. The core offering is an integrated software suite for molecular modeling, simulations, and analytics, which clients access through software licensing or collaborative research agreements, and may also participate in wholly-owned or collaborative drug-discovery programs. The company differentiates itself with a long history since 1990 and a global footprint, combining a full end-to-end platform with direct drug-discovery partnerships and extensive services. Its goal is to advance science and talent by strengthening its platform and helping partners discover and develop new medicines using computational methods and collaborative programs.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

1990

Simplify Jobs

Simplify's Take

What believers are saying

  • Hosted software expansion supports recurring revenue and broader enterprise adoption.
  • Top pharmaceutical customers are expanding platform access, lifting annual contract value.
  • AI partnerships with Anthropic and Eli Lilly strengthen product differentiation and workflow integration.

What critics are saying

  • Hosted migration compresses software gross margin before scale benefits arrive.
  • SGR-1505 remains Phase 1, so clinical failure can erase pipeline value.
  • Net dollar retention at 100% signals weaker expansion across the installed customer base.

What makes Schrödinger unique

  • Physics-based computational platform serves pharma, biotech, materials, academia, and governments.
  • Founded in 1990, Schrödinger combines software licensing with proprietary drug discovery programs.
  • Global reach spans customers and collaborators in more than 70 countries.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Schrödinger who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Paid Vacation

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Mar 1st, 2026
Schrödinger reports $255.9M revenue and 72% undervaluation as AI drug platform narrows losses

Schrödinger, a computational drug discovery and AI company, reported full-year 2025 revenue of $255.9 million with a narrowed net loss of $103.3 million. Despite positive financials, the stock has underperformed, trading at $12.06 per share. The company's share price shows mixed returns: 13.67% over 30 days and 32.93% year-to-date, whilst longer-term investors face losses despite 45.94% one-year and 82.66% five-year returns. Analysts suggest the stock trades at a significant discount to its estimated fair value of $43.20 per share, representing potential 72.1% upside. This valuation assumes strong recurring software revenue, robust margins and successful drug pipeline development. However, risks remain if clinical programmes fail or operating losses persist longer than expected.

Yahoo Finance
Feb 26th, 2026
Schrödinger reports $256M revenue, $5B milestone potential as firm shifts to cloud contracts

Schrödinger reported 2025 revenue of $256 million, up 23% year-over-year, with software revenue of $199.5 million and total annual contract value of approximately $198.5 million. The company narrowed its net loss to $103 million from $187 million in 2024 and ended the year with $402 million in cash. The company is accelerating a shift from on-premise to hosted, cloud contracts, with 23% hosted in 2025 and targeting roughly 75% by 2028. Management noted this transition will materially affect reported revenue timing and margins, with approximately $2–3 million revenue impact per 1% increase in hosted mix. Schrödinger highlighted its therapeutics portfolio with potential milestones up to $5 billion and upcoming clinical readouts, including WEE1/Myt1 Phase I data expected in Q2. The company is also exploring agentic AI integration with Anthropic.

Yahoo Finance
Feb 26th, 2026
Schrödinger hits $256M revenue with 23% growth amid hosted model transition

Schrodinger Inc reported total revenue of $256 million for 2025, marking 23% growth, with software revenue at $199.5 million and drug discovery revenue at $56.4 million. The company maintains a cash position of $402 million. However, the company's transition to a hosted model impacted margins, with software gross margin declining to 74% from 80% in 2024. Net loss narrowed to $103 million from $187 million the previous year. Annual contract value grew 4% to $198.5 million, whilst net dollar retention fell to 100% from over 110% previously, reflecting challenging pharma and biotech market conditions. For 2026, Schrodinger guides annual contract value between $218 million and $228 million, representing 10% to 15% growth, with drug discovery revenue expected between $55 million and $65 million.

Silicon Canals
May 14th, 2025
Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

NEW YORK - (BUSINESS WIRE) - Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy.

America's Charities
Apr 30th, 2025
Sustainability News provided by 3BL

Schrödinger launched its first company-wide Volunteer Month, during which every office globally participated in local community service activities.

INACTIVE